is.. looking for better days! They ARE coming, you know!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
congrats on your purchase, I guess
back at it's yearly low, more or less.
.0026
DOA, folks
any possibility in a pie-in-the-sky miracle looks pretty dim...
shoulda bailed around a penny-
next set of pumpers will assuredly show up months down the road and I'll have my sell order set well ahead of that time.
glta
Down to .0066.
Looks like the patience has worn off and the frenzied speculation ebbed.
Couldn’t get my sell orders filled so back to being a bagholder I guess
Was nice to dream a bit!
I suppose we'll see...
sentiment/enthusiasm has waned and the pps is now sliding down closer to the inert levels it was before all this speculation.
good luck
yeah- big
down below a penny again.
was hopeful that after all these years the rumours of r/m were going to be true.
looks now like a typical but patient P&D with some folks raking it in near 2cents
hey guys!
some OLDDDDD timers showing up here?
happy holidays
And look at it run!!!
Down of course.
Obviously we need another round of insider selling so it magically and oh so briefly jumps over 15 for a nanosecond so they get theirs... then just as quickly back down for all us peons.
What a piece of crap this stock has become
Yup- another blood letting
Looks like AT LEAST 5 buck Drop from Monday am.
But earnings were so goooooood.
??
and boom--- just like that
15 held firm for like, uh, 90 seconds
now there's a fleet race to see how low into the 14's this will go.
never seen such a flood for the door after earnings that logically should have cemented VCEL as a legitimate company (to invest in).
shades of the penny stock days of Aastrom
is that where this is really heading?
hard to fathom, but so has a 20%+ drop and declining fast in less that a day and a half.
Edit PART TWO:
from 6 to 8 and now basically 10%
that's 20 percent in less than two days...
on 'stellar' earnings?
a miss by a frog hair?
WTF
and another 6+% down already-
with no bottom in sight.
hard to spin this in anyway but the company failed investors.
they've got some 'splainin to do....
edit: like 30 seconds later
down over EIGHT percent
freakin garbage
back toward 14's
fact
stock is down nearly 3bucks and nearly 16% AFTER the 'beat/meet ER..."
virus fears?
yesterday it wasn't a factor.
so why, after 'beat/meet ER....' is this thing down as if it missed by a gazillion percent?
so define reasonable... is it because VCEL really is as high as it's gonna be for who knows how long?
apparently it's just one of those securities that defies logic-
down on bad news
down on good news
bullish sign?
stock is down 16%....
15% drop and back into the 15's
manipulation?
is that what has been going on for the past year??
high expectations not met-
doubters reaping the benefits.
this stock needs to beat by like 3x in order to rise.
or show a pulse.
pathetic.
And down 10% in pre
I’d get it if there was a big run into earnings-
Last year, near 21$ without this additional revenue
If there was a bit of a miss or even a perceived miss, then I’d not be surprised.
But this has stumbled for close to a year-
Shows good biz numbers- and we’re potentially back to where we were months ago. At best.
What the hell is it gonna take?
Not looking good premarket
Hopes dashed?
would love to see the momentum continue
been languishing too long.
good article on epicel sales
Seeking Alpha
Summary
Unexpectedly strong Epicel revenue growth carries Vericel to another strong quarter of revenue gains and positive net income.
The company is showing more balance in revenue, adding stability to the company and its share price.
Despite the recent NexoBrid acquisition, Vericel remains in acquisition mode, and it has the cash to do so.
Technically, the share price is forming a high flag right below major resistance, setting the stage for a long-awaited breakout above $20.
https://seekingalpha.com/article/4309405-surprise-jump-epicel-sales-highlights-outstanding-3q-vericel
all in all, some good stuff
lets hope it strengthens the legs of this pup.
good luck
by the way: is there anyone left on this board????
thanks for the correction-
I have it my calendar as today.
re: this morning-
work and work meetings really get in the way of life!
good luck!
could this really heading to 14's?
ahead of today's conference?
15.38 currently
spin some positive on this folks, because there's been nothing but crap indicators, downward pressure, inconclusive trading action and not a peep from the company except to announce more insider selling (planned or not).
glta
If you have the time-
and the intestinal fortitude, sure- hang in there.
but another day dipping into the 15s? for no apparent reason?
hard to stomach
good luck!
Dow Up-
VCEL down
Down down-
VCEL down
this one is really hard to figure...
not a lot of exposure to tradewar scenario (supplies perhaps?)
not too much worry about recession effects (people still need healthcare)
forecast up
revs up
something in the pipeline (nexobrid)
seemingly tons of institutional interest/buying
just what is the issue here that won't allow the PPS to get anywhere near where it was prior to excellent earnings?
smh
sadly, I'd take that in a heart beat.
very painful to watch this stock over the last week.
hopefully something, anything will turn it around.
Perhaps I spoke too soon
After today, last week looks like seashells and balloons!
Down 5% from Friday with hours to go.
Filling some gaps or covering some short post?
Hopefully.
Otherwise yikes
A week to forget
Wow-
So much promise at the end of last week. Pps pushes 20.
New week- shootings China tariffs market flop takes vcel straight down.
Pretty darn good earnings report ends up doing nada.
Spike to high 19’s then straight down again to 17’s.
Malaise and anemic trading with tepid interest for the rest of the week.
Closes, no surprise, just above LOD.
High hopes dashed.
Back to watching paint dry.
A week that could have been!
Wasted.
Good weekend all!
Mr Sunshine
Short interest up a bit
Gotta have big kahooonies to feel confident shorting such an unpredictable stock.
Know the swings I suppose.
Vericel Corporation (NASDAQ:VCEL) had an increase of 1.61% in short interest. VCEL’s SI was 6.13 million shares in August as released by FINRA. Its up 1.61% from 6.03M shares previously. With 576,400 avg volume, 11 days are for Vericel Corporation (NASDAQ:VCEL)’s short sellers to cover VCEL’s short positions. The stock decreased 2.63% or $0.49 during the last trading session, reaching $18.11. About 579,405 shares traded or 15.89% up from the average. Vericel Corporation (NASDAQ:VCEL) has risen 91.20% since August 8, 2018 and is uptrending. It has outperformed by 91.20% the S&P500. Some Historical VCEL News: 08/05/2018 – Vericel 1Q Loss/Shr 21c; 11/05/2018 – PNC Financial Services Group Buys New 1.7% Position in Vericel; 30/05/2018 – Vericel Corp Announces Proposed Public Offering of Common Stk; 14/05/2018 – Next Century Growth Investors Buys New 1% Position in Vericel; 17/05/2018 – Vericel 31.3% Owned by Hedge Funds; 23/03/2018 – Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years; 05/04/2018 – Vericel Investor Day Scheduled By Trout Group for Apr. 11; 20/04/2018 – DJ Vericel Corporation, Inst Holders, 1Q 2018 (VCEL); 12/03/2018 Vericel to Host Analyst and Investor Day on April 11, 2018
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $795.23 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.
Among 2 analysts covering Vericel Corp (NASDAQ:VCEL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vericel Corp had 9 analyst reports since February 26, 2019 according to SRatingsIntel. Oppenheimer maintained Vericel Corporation (NASDAQ:VCEL) on Tuesday, February 26 with “Buy” rating. Oppenheimer maintained the stock with “Buy” rating in Thursday, March 7 report. BTIG Research maintained the shares of VCEL in report on Thursday, June 20 with “Buy” rating. On Tuesday, February 26 the stock rating was maintained by BTIG Research with “Buy”.
insane swings this AM
you'd anticipate some of that, but sheesh.
HOD 19.77 then LOD at 17.55?
not in on CC so I'm not sure if mgmt dropped a bomb, but wow!
Beat revs by almost 2 million
And eps by .02
Raised guidance
It was pushing 20 just a few days ago before all this market nonsense-
Might take a bit to get back there, but we have a nice foundation for sure from here
Good luck!
Hard to read as overall market reaction to Trump/China spat affected vcel as well.
Lots of positive views in Zacks er al.
Before bell earnings followed the very next day with a conference?
We’ll see.
I fear that even with a good report the overall market jitters will be the proverbial wet blanket.
Vericel to Present at the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019
8:00 AM ET 8/1/19 | GlobeNewswire
Vericel to Present at the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 39(th) Annual Canaccord Genuity Growth Conference in Boston, Massachusetts on Thursday, August 8, 2019 at 12:00pm Eastern Time.
A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI(R) (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel(R) (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid(R) , a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company's website at www.vcel.com.
Epicel(R) and MACI(R) are registered trademarks of Vericel Corporation. NexoBrid(R) is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. (c) 2019 Vericel Corporation. All rights reserved.
Did The Underlying Business Drive Vericel's (NASDAQ:VCEL) Lovely 767% Share Price Gain?
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. You won't get it right every time, but when you do, the returns can be truly splendid. One bright shining star stock has been Vericel Corporation (NASDAQ:VCEL), which is 767% higher than three years ago. Unfortunately, though, the stock has dropped 5.8% over a week. But this could be related to the soft market, with stocks selling off around 0.9% in the last week.
It really delights us to see such great share price performance for investors.
Check out our latest analysis for Vericel
Vericel isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
In the last 3 years Vericel saw its revenue grow at 22% per year. That's much better than most loss-making companies. And it's not just the revenue that is taking off. The share price is up 105% per year in that time. It's always tempting to take profits after a share price gain like that, but high-growth companies like Vericel can sometimes sustain strong growth for many years. In fact, it might be time to put it on your watchlist, if you're not already familiar with the stock.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think Vericel will earn in the future (free profit forecasts).
A Different Perspective
It's nice to see that Vericel shareholders have received a total shareholder return of 78% over the last year. That gain is better than the annual TSR over five years, which is 41%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.
Oppenheimer is an interesting case-
I have to look more into their performance history regarding their calls.
As far as institutional ownership is concerned, if they’re buying, great! Often signifies stability or growth.
Here’s a real good article on pros/cons of institutional ownership
https://www.investopedia.com/articles/stocks/07/insitutional-owners.asp
Best of luck to you and us all!
Yeah, a few articles mention that.
Interesting
Zacks Investment Research upgraded shares of Vericel (NASDAQ:VCEL) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. The firm currently has $22.00 target price on the biotechnology company’s stock.
According to Zacks, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. “
Get Vericel alerts:
Several other analysts also recently weighed in on VCEL. BidaskClub downgraded YY from a sell rating to a strong sell rating in a research note on Tuesday, July 23rd. Oppenheimer decreased their target price on 2U from $83.00 to $67.00 and set an outperform rating for the company in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $22.98.
Shares of NASDAQ:VCEL opened at $19.42 on Tuesday. The firm’s 50 day simple moving average is $18.46. Vericel has a twelve month low of $9.70 and a twelve month high of $21.00. The company has a market cap of $852.75 million, a P/E ratio of -138.71 and a beta of 2.84. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.16 and a current ratio of 8.47
analyst's Expect Vericel Corp (NASDAQ:VCEL) Will Announce Quarterly Sales of $24.30 Million
Tuesday, July 30th, 2019
Ned Boundy
Equities analysts predict that Vericel Corp (NASDAQ:VCEL) will post sales of $24.30 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Vericel’s earnings, with the highest sales estimate coming in at $24.50 million and the lowest estimate coming in at $24.10 million. Vericel reported sales of $19.01 million during the same quarter last year, which indicates a positive year-over-year growth rate of 27.8%. The company is expected to report its next earnings results on Monday, August 5th.
According to Zacks, analysts expect that Vericel will report full-year sales of $113.69 million for the current year, with estimates ranging from $113.48 million to $113.90 million. For the next fiscal year, analysts forecast that the company will post sales of $146.18 million, with estimates ranging from $141.85 million to $150.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Vericel.
Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). Vericel had a negative net margin of 3.51% and a negative return on equity of 3.40%. The firm had revenue of $21.81 million for the quarter, compared to the consensus estimate of $22.51 million. During the same period in the prior year, the firm posted ($0.21) earnings per share. The company’s revenue for the quarter was up 21.0% on a year-over-year basis.
A number of equities research analysts have recently issued reports on VCEL shares. Oppenheimer lowered their price target on shares of 2U from $83.00 to $67.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. Finally, BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a research note on Saturday, June 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $22.98.
In other Vericel news, Director Steven C. Gilman sold 7,500 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $16.81, for a total transaction of $126,075.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Gerard J. Michel sold 17,500 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $15.62, for a total transaction of $273,350.00. Following the transaction, the chief financial officer now owns 131,422 shares in the company, valued at $2,052,811.64. The disclosure for this sale can be found here. Insiders sold 42,500 shares of company stock worth $697,275 over the last ninety days. 4.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of VCEL. Advisory Services Network LLC grew its position in Vericel by 1,400.0% during the first quarter. Advisory Services Network LLC now owns 1,500 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 1,400 shares during the last quarter. Pearl River Capital LLC bought a new position in Vericel during the first quarter valued at approximately $72,000. Great West Life Assurance Co. Can bought a new position in Vericel during the fourth quarter valued at approximately $78,000. SG Americas Securities LLC bought a new position in Vericel during the first quarter valued at approximately $109,000. Finally, First Quadrant L P CA bought a new position in Vericel during the first quarter valued at approximately $115,000. Institutional investors and hedge funds own 85.16% of the company’s stock.
Shares of Vericel stock traded down $0.30 on Friday, reaching $19.53. The stock had a trading volume of 5,061 shares, compared to its average volume of 489,178. Vericel has a 1 year low of $8.95 and a 1 year high of $21.00. The stock has a market capitalization of $862.83 million, a P/E ratio of -140.36 and a beta of 2.84. The company has a current ratio of 8.47, a quick ratio of 8.16 and a debt-to-equity ratio of 0.24. The stock’s 50 day moving average price is $17.26.
“Growing number” seeking alternatives
For those with cartilage damage, new treatments are also emerging. “There are newer agents that we can use to inject into the hip and knee that may be safer for alleviating pain, with little to no risk for complications,” says Dr. Bhatia.
This includes a technique that uses matrix-induced autologous chondrocyte implantation (MACI) to restore knee cartilage. According to Dr. Bhatia, the first step in MACI involves taking a sample of the patient’s cartilage from a non-weight-bearing part of the knee. The tissue is sent to a lab, where cells are embedded in a special collagen membrane that promotes tissue growth. During surgery, the new tissue, called the MACI membrane, is trimmed to the desired size and shape, and secured to the bone.
Stay Active, Longer
As the number of joint replacement surgeries continues to grow, Northwestern Medicine Hip and Knee Joint Preservation Center at Central DuPage Hospital is serving a growing number of patients seeking alternative options. “Joint replacement produces outstanding results for people,” says Dr. Bhatia. “But if we can help individuals avoid joint replacement, or delay it, it helps keep them more active in their life. That’s what we’re trying to achieve.”
https://www.nm.org/healthbeat/medical-advances/new-therapies-and-drug-trials/what-you-need-to-know-about-protecting-your-joints
Now slowwwwly chipping away at more LODs
17’s not far?
Low volume- maybe just markets being made.
But ugh! Nonetheless
sentiments?
pretty quiet here.
have been out for a bit, but saw the resurgence to near 20-
now back in 18's.
thoughts?
Global $25.4 Bn Tissue Engineering (Technologies and Therapeutic) Markets, 2015-2018 & 2019-2024: Orthopedics, Musculoskeletal & Spine Applications Corner the Largest Share GlobeNewswire July 02, 2019
Dublin, July 02, 2019 (GLOBE NEWSWIRE) -- The "Tissue Engineering: Technologies and Therapeutic Areas - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.
Overall, the Tissue Engineering market, globally, for 2019 is projected to touch US$25.4 billion.
Organs developed using Tissue Engineering are highly durable and efficient, with applications gaining ground in areas, such as surgical manipulation of tissues and prosthetics for cardiac, cancer and orthopedic uses. The technology has reached a stage where the products offer a reduced rate of rejection by the body, which would further propel the market for Tissue Engineering. Though North America is the leading global region for revenues garnered from Tissue Engineering, Asia-Pacific is likely to outpace all other regions by posting the fastest CAGR over the analysis period.
2. KEY MARKET TRENDS
2.1 Latest Developments in Tissue Engineering
...
2.6 Plasma Protein Shows Promise for Making Wound-Healing Tissue Scaffolds
2.7 Speed of Bone Repair Process May be Accelerated with the Help of Two Types of Cells
2.8 New Therapy Developed for Osteomyelitis
...
2.12 Patients with Cartilage Defects Get the Boon of Cartilage Tissue Engineering
3. KEY GLOBAL PLAYERS
.....
Vericel Corporation (United States)
4. KEY BUSINESS AND PRODUCT TRENDS
....
Vericel Corporation and Innovative Cellular Therapeutics Co., Ltd. Join Forces on Advanced Cell Therapy Portfolio
....
Vericel Highlights MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Meeting
6. NORTH AMERICA
Major Market Players
...
Vericel Corporation (United States)
https://www.researchandmarkets.com/reports/4790912/tissue-engineering-technologies-and-therapeutic?utm_source=GNDIY&utm_medium=PressRelease&utm_code=wbn66b&utm_campaign=1271892+-+Global+%2425.4+Bn+Tissue+Engineering+(Technologies+and+Therapeutic)+Markets%2c+2015-2018+%26+2019-2024%3a+Orthopedics%2c+Musculoskeletal+%26+Spine+Applications+Corner+the+Largest+Share&utm_exec=chdo54prd
Tissue Engineering: Technologies and Therapeutic Areas – A Global Market Overview
ID: 4790912 Report June 2019 Region: Global 374 Pages Industry Experts
DESCRIPTION
TABLE OF CONTENTS
SAMPLES
COMPANIES MENTIONED
METHODOLOGY
OPTIONS
FEATURED COMPANIES
Acelity L.P. Inc.
Baxter International Inc.
Cerapedics, Inc.
Depuy Synthes
Mesoblast Ltd
RTI Surgical®
MORE
PRINTER FRIENDLY
SEND TO A FRIEND
Organs developed using Tissue Engineering are highly durable and efficient, with applications gaining ground in areas, such as surgical manipulation of tissues and prosthetics for cardiac, cancer and orthopedic uses. The technology has reached a stage where the products offer a reduced rate of rejection by the body, which would further propel the market for Tissue Engineering. Though North America is the leading global region for revenues garnered from Tissue Engineering, Asia-Pacific is likely to outpace all other regions by posting the fastest CAGR over the analysis period.
Orthopedics, Musculoskeletal & Spine applications corner the largest share of the global market for Tissue Engineering in terms of application, which is estimated at 60.5% or US$13.5 billion in 2018 and is projected to reach US$34.7 billion by 2024 at a CAGR of 17.1% between the two years. Overall, the Tissue Engineering market, globally, for 2019 is projected to touch US$25.4 billion.
Research Findings & Coverage
The global market for Tissue Engineering analyzed in this report with respect to Material Types and Applications
The study explores the aforementioned categories of Tissue Engineering in each major region/country worldwide for the analysis period
Biomaterials for Tissue Engineering Get Innovative
Successful Creation of Functioning Kidney Tissue by Researchers
Human Trials of Novel Tissue-Engineered Blood Vessel Replacements Now Closer
Plasma Protein Shows Promise for Making Wound-Healing Tissue Scaffolds
Key business trends focusing on product innovations/developments, M&As, JVs, and other recent industry developments
Major companies profiled - 38
The industry guide includes the contact details for 270 companies
Product Outline
The report analyzes the market for the following material types of Tissue Engineering including:
Biomimetic Materials
Composite Materials
Nanocomposite Materials
Nanofibrous Materials
The market for applications of Tissue Engineering explored in this report includes:
Cancer
Cardiology & Vascular
Dental/Oral
Neurology
Orthopedics, Musculoskeletal & Spine
Skin/Integumentary
Others
Analysis Period, Units and Growth Rates
The report reviews analyze and project the global Tissue Engineering market for the period 2015-2024 in terms of US$ and the compound annual growth rates (CAGRs) projected from 2018 through 2024
Geographic Coverage
North America (The United States, Canada, and Mexico)
Europe (France, Germany, Italy, The United Kingdom and Rest of Europe)
Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)
South America (Argentina, Brazil and Rest of SA)
Rest of World